LAS VEGAS, Aug. 24, 2022 /PRNewswire/ — EBET, Inc. (NASDAQ:EBET), a leading global operator and provider of advanced wagering products, announced today that Jon Najarian has joined the company ranks as an Advisor.
Genmab Announces FDA Acceptance For Priority Review Biologics License Application For Epcoritamab For The Treatment Of Relapsed/Refractory Large B-Cell Lymphoma
Epcoritamab BLA accepted for FDA Priority review; FDA action date is May 21, 2023
Epcoritamab could become the first subcutaneous bispecific antibody approved for the treatment of LBCL
BLA submission supported by
Epcoritamab BLA accepted for FDA Priority review; FDA action date is May 21, 2023
